BWAY Brainsway

BrainsWay to Participate in Two Upcoming Investor Conferences

BrainsWay to Participate in Two Upcoming Investor Conferences

CRESSKILL, N.J. and JERUSALEM, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 6th Annual Israel Conference on Thursday, November 12 at 7:00 AM ET. The Company will also participate in one-on-one investor meetings at the Oppenheimer Fall MedTech Summit held on November 12.

About BrainsWay

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders. To learn more, please visit .

Contacts:

BrainsWay:

Judy Huber

SVP and Chief Financial Officer

Investors:

Bob Yedid

LifeSci Advisors

646-597-6989

EN
02/11/2020

Underlying

BWAYBrainsway

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Brainsway

 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for...

BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD) Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response and remission The accelerated protocol is now commercially available in the United States, expanding patient and provider access BURLINGTON, Mass. and JERUSALEM, Sept. 16, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neuros...

September 16, 2025 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Targets Expansion of its Total Addressable Market through a ...

BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd. This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief’s breakthrough Proliv™Rx device is pending Premarket Approval from the U.S. FDA, and if granted, will become the first FDA-cleared medical device for MDD treatment that can be delivered outside of the clinic BURLINGTON, Mass. and JERUSALEM, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BrainsWa...

August 21, 2025 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health The Investment is part of BrainsWay’s ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Mana...

August 20, 2025 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Reports Second Quarter 2025 Financial Results and Operationa...

BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance obligations increased by 25% YOY to $62 million Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in ad...

August 13, 2025 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Champions TMS Education with Sponsorship of Two Free CME Cou...

BrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health Professionals BURLINGTON, Mass. and JERUSALEM, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- , a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its underwriting of two new designed to expand clinician knowledge and confidence in the use of . These online, no-cost CME activities aim to deepen understanding of the robust clinical evidence supporting TMS, clarify distinctions between Deep TMS™—a proprietary BrainsWay technology—and fir...

July 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch